iBio Inc., a biotechnology corporation, announced the scheduling of its 2024 Annual Meeting of Stockholders to be held on November 21, 2024. The meeting will address the election of three Class I director nominees, the ratification of Grassi & Co., CPAs, P.C. as the independent registered public accounting firm for the fiscal year ending June 30, 2025, and an advisory vote on the compensation of named executive officers. Stockholders of record as of October 9, 2024, are entitled to vote at the meeting. The Board of Directors recommends voting for each of the director nominees, for the auditor ratification, and for the executive compensation proposal. The company has also entered into several agreements with RubrYc Therapeutics, Inc., including an asset purchase agreement to acquire substantially all of RubrYc's assets. Additionally, iBio has entered into a side letter with Lynx1 Capital Management LP, granting Lynx1 the right to nominate a director for a three-year term starting with the 2024 Annual Meeting.

iBio Inc., a biotechnology corporation, announced the scheduling of its 2024 Annual Meeting of Stockholders to be held on November 21, 2024. The meeting will address the election of three Class I director nominees, the ratification of Grassi & Co., CPAs, P.C. as the independent registered public accounting firm for the fiscal year ending June 30, 2025, and an advisory vote on the compensation of named executive officers. Stockholders of record as of October 9, 2024, are entitled to vote at the meeting. The Board of Directors recommends voting for each of the director nominees, for the auditor ratification, and for the executive compensation proposal. The company has also entered into several agreements with RubrYc Therapeutics, Inc., including an asset purchase agreement to acquire substantially all of RubrYc's assets. Additionally, iBio has entered into a side letter with Lynx1 Capital Management LP, granting Lynx1 the right to nominate a director for a three-year term starting with the 2024 Annual Meeting.